Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to glutamate by the mitochondrial enzyme glutaminase.
Introduction
Tumor cells utilize a variety of oncogenically-and environmentally-driven metabolic pathways to meet the bioenergetic and biosynthetic demands of rapid and sustained growth (1, 2) . One of the key nutrients that fuels the growth of many cancers is the amino acid glutamine, the most abundant amino acid in plasma (3, 4) . A critical step in the utilization of glutamine is its conversion to glutamate by the mitochondrial enzyme glutaminase (5, 6) . Glutamate and glutamate-derived metabolites in turn support a number of crucial cellular pathways including the tricarboxylic acid (TCA) cycle, redox balance, and amino acid synthesis.
Suppression of the broadly expressed form of glutaminase (encoded by the gene GLS) with either small molecule inhibitors or by genetic knockdown has anti-tumor activity across a variety of tumor types, including lymphoma, glioma, breast, pancreatic, non-small cell lung, and renal cancers (6) (7) (8) (9) (10) (11) (12) (13) (14) .
Additionally, elevated GLS expression is associated with high grade and metastatic breast cancer (15) . In particular, triple-negative breast cancer (TNBC) primary tumors and cell lines have elevated GLS mRNA; this is associated with high glutamine consumption and/or enhanced reliance on exogenous glutamine for survival in vitro (14, 16) . Together, these observations highlight the critical connection between tumor growth and glutamine utilization and suggest that glutaminase inhibitors may provide therapeutic benefit in the treatment of a variety of cancers, including TNBC.
Several small molecule inhibitors of glutaminase have been reported (6, (17) (18) (19) . Glutamine analogs, 6-diazo-5-oxo-L-norleucine, azaserine and acivicin, bind irreversibly to the active site of a number of glutamine-utilizing enzymes, including glutaminase (20) . Clinical studies with these compounds showed limited antitumor activity but their development was restricted by severe toxicities, potentially due to the broad antagonism of multiple glutamine utilizing enzymes and transporters (17) . More recently, two allosteric inhibitors of glutaminase have been reported, compound 968 and BPTES (bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide), that act by distinct mechanisms (6, 18, 21) . The allosteric mechanism for BPTES (and BPTES analogs) entails formation of an inactive glutaminase homotetramer through the binding of two inhibitor molecules at the interface between a pair of homodimers (18, 22, 23) . Several groups have reported anti-tumor activity for BPTES in lymphoma, breast, glioma, pancreatic, lung, and renal tumor types (7, 9, (11) (12) (13) 24) . However the moderate potency, poor metabolic stability, and low solubility of BPTES limit its potential for clinical development.
We report here the discovery and characterization of CB-839, a potent and selective inhibitor of efficacy in breast cancer xenograft models, both as a single agent, and in combination with the standard-of-care agent paclitaxel. Together these results support the notion that glutamine utilization is a critical growth and survival pathway in TNBC and that glutaminase inhibition with CB-839 may provide a therapeutic benefit for patients with TNBC and other glutamine-dependent tumors.
Material and Methods

Chemistry
BPTES was prepared as previously described (25) . The synthesis and chemical characterization of CB-839 ( Fig. 1A ) is described in (26) , wherein it is referenced as #670.
Biochemical analysis
The inhibitory activities of BPTES and CB-839 on recombinant human GAC (rHu-GAC) were measured in a coupled biochemical assay monitoring glutamate production with the NADPH-dependent enzyme glutamate dehydrogenase by a method modified from that described previously (15) , as detailed in the Supplementary Methods. To measure time-dependence of inhibition, rHu-GAC was pre-incubated with inhibitor prior to measurement of glutaminase activity with the coupled assay. Recovery from inhibition after a 90 minute pre-incubation of rHu-GAC and inhibitor was determined by measuring glutaminase activity at various timepoints following separation of free inhibitor by gel filtration on Zeba Spin Desalting Columns (Thermo). Glutaminase activity was measured in homogenates prepared from tumor cell lines and mouse tissues using the coupled assay as described in the Supplementary Methods.
Cellular assays
The breast cell lines, BT-20, BT-549, Hs578T, HCC38, HCC1806, MCF-10A, HCC70, MDA-MB-231, MDA-MB-436, HMC-1-8, HCC1395, HCC1187, Hs739.T, MDA-MB-468, HCC1954, MCF-7, Hs343.T, HCC1428, DU4475, AU-565, T47D, Sk-Br-3, and MDA-MB-175-VII were obtained from the American Type Culture Collection (ATCC). The JIMT-1 and MX-1 cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) and Cell Line Services (CLS), Germany, respectively. All cell lines were passaged for fewer than 6 months after resuscitation. The ATCC, CLS, and DSMZ cell lines were authenticated by Short Tandem Repeat (STR) analysis. Cell lines for viability, metabolite, glutaminase activity, and Western blot assays were maintained and assayed in RPMI-1640 supplemented with 2mM glutamine and 10% FBS at 37°C with 5% CO 2 with the exception of the MCF10A which were maintained as described previously (27) . For the media depletion and Seahorse assays, HCC1806 and T47D were obtained from the MD Anderson Characterized Cell Line Core [verified using AmpF/STR Identifier kit (Applied Biosystems)] and cultured in Dulbeccos' Modified Eagles' Media (DMEM) with 5% FBS at 37°C in 5% CO 2 atmosphere.
For viability assays, all cell lines were treated with CB-839 at the indicated concentrations for 72 h in duplicate wells and analyzed for anti-proliferative effects using Cell Titer Glo (CTG) (Promega). For all cell lines except MDA-MB-175, SUM149PT, Hs343.T, HCC38, and BT20 the results presented represent an average across at least two independent experiments. IC 50 values were calculated using a four parameter curve fit (Graphpad Prism). Relative cell loss or proliferation in the presence of 1 µM CB-839 or in glutamine-free media was determined by comparing the CTG signals measured at time (t) = 72 h under experimental conditions (CTG exp_72 ) with both the CTG signal at t =72 h for vehicle (0.5% DMSO) treated cells (CTG DMSO_72 ) and the CTG signal measured at t = 0, the time of CB-839 addition or glutamine withdrawal (CTG 0 ), using the following equations: % cell loss (when CTG exp_72 < CTG 0 ) = 100 x (CTG exp_72 -CTG 0 )/CTG 0 ; % cell proliferation (when CTG exp_72 > CTG 0 ) = 100 x (CTG exp_72 -CTG 0 )/ (CTG DMSO_72 -CTG 0 ).
Western blot analysis
Lysates were prepared from cell pellets and protein amounts quantitated as described in Supplementary Methods. Lysate proteins (20 µg/lane) were denatured by boiling in SDS-sample buffer, resolved on 7% Tris-acetate gels (together with Novex sharp pre-stained molecular weight standards; Life Technologies), and transferred to nitrocellulose membranes. Nitrocellulose-immobilized proteins were probed with antibodies recognizing both GAC and KGA forms of glutaminase (1:5000; AB156876, Abcam), glutamine synthetase (1:1000; HOOOO2752-M02, Abnova), glutaminase-2 (1:1000; NBPI-76544, Novus Biological), and beta-actin (1:10,000; A5441, Sigma-Aldrich) followed by HRP-coupled anti-rabbit or anti-mouse antibodies (1:5000; NA934V and NA931V, GE Healthcare). Bands were revealed by chemiluminescence (Thermo Scientific) and images were captured with the FluorChem HD2 system (Protein Simple).
Further validation of the glutaminase antibody used for Western blotting and the mobility of the bands detected is provided in the Supplementary Methods. Nglutamate as the internal standard and analyzed for metabolite levels by LC/MS/MS using the SCIEX API4000 (Applied Biosystems). Mouse tissue homogenates were also analyzed for CB-839 levels using a similar method except that 50 nM carbamazepine was used as the internal standard.
Metabolite and CB-839 measurements by LC/MS
Depletion of substrates in medium
For experiments quantifying metabolite consumption or production in tissue culture media, cells were incubated in DMEM with 5 mM glucose and 0.5 mM glutamine (no serum) for 6 h. Media concentrations of glucose, lactate, glutamine, and glutamate were quantified using the YSI 2900
Biochemistry Analyzer (YSI Life Sciences).
Seahorse oxygen consumption rates
To quantify rates of oxygen consumption, cells were seeded (8 to 10K cells/well) in DMEM, 5% FBS, on XF96 V3 PET plates (Seahorse Biosciences). After the cells attached overnight, the medium was exchanged with DMEM (5 mM glucose with or without 0.5 mM glutamine, no FBS, no bicarbonate). The plates were immediately loaded on the Seahorse XF96 Bioanalyzer (Seahorse Biosciences) for quantification of oxygen consumption rates (OCR). To determine their effects on OCR, compounds were added sequentially (CB-839 or DMSO, 1 μg/mL oligomycin, and 1 μM antimycin).
In vivo studies
CB-839 and metabolite levels were measured in tumors and tissues excised from female Scid/Bg mice (Charles River Laboratories; age 6-9 weeks, 17-23 gm) implanted with HCC1806 cells in the mammary fat pad (2.5 X 10 6 cells/mouse; tumor volume ~500 mm 3 
Results and Discussion
CB-839 is a potent and selective glutaminase inhibitor.
The small molecule BPTES was previously described as an allosteric glutaminase inhibitor active against both splice variants of the GLS gene, GAC and KGA (reported Ki's between 0.2 and 3 µM), but not the liver form of glutaminase, encoded by the GLS2 gene (18, 19, 21, 22) . CB-839 (Fig. 1A) is a novel glutaminase inhibitor that exhibits low nanomolar potency in biochemical and cellular assays and has good oral bioavailability. In a biochemical assay with recombinant human GAC (rHu-GAC), the potency and kinetic behavior of CB-839 was distinct from BPTES. Unlike BPTES, CB-839 exhibited time dependent ( Fig. 1B and 1C ) and slowly reversible kinetics (Fig. 1D) . IC 50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for ≥1 h were < 50 nM, at least 13-fold lower than with BPTES. Furthermore, upon removal of free inhibitor, recovery of rHu-GAC activity was rapid for BPTES (<3 minutes) and slow for CB-839 (t 1/2 = 45 minutes at 25°C). This altered kinetic behavior was also associated with a change in the mode of inhibition. BPTES displayed a predominantly uncompetitive mechanism characterized by dose dependent decreases in both V max and the K m for glutamine ( Supplementary Fig. S1A ) and a shift toward greater potency with increasing glutamine concentrations ( Supplementary Fig. S1C ), consistent with previous reports (18, 21) . In contrast, CB-839 behaved as a primarily non-competitive inhibitor impacting V max but with minimal effect on K m (Supplementary Fig.   S1B ) and displaying a potency that was independent of glutamine concentration ( Supplementary Fig.   S1D ). The ability of CB-839 to inhibit native glutaminase in mouse tissue homogenates was also measured using a coupled biochemical assay (see Materials and Methods). Treatment of homogenates prepared from kidney and brain, two tissues that express the GLS gene products (28, 29) , with CB-839 for 1 h resulted in glutaminase inhibition (IC 50 =20-30 nM) comparable to that obtained with rHu-GAC ( gene product (28, 29) with CB-839 resulted in no detectable glutaminase inhibition. This result is consistent with the reported high degree of selectivity of BPTES for GLS over GLS2 gene products (18, 22) . Taken together, these results demonstrate that although CB-839 and BPTES share a similar allosteric binding mechanism and selectivity profile, CB-839 has increased potency and distinct kinetic behavior, exhibiting a slow-on/slow-off mechanism.
CB-839 blocks glutamine utilization in TNBC cells.
TNBC primary tumors and many cell lines are reported to have high expression of glutaminase (GLS gene products) and low expression of glutamine synthetase (GLUL gene product), an enzyme that produces glutamine from glutamate (14, 16) . This expression pattern is associated with high glutamine consumption and a dependence of TNBC cell line growth on exogenous glutamine, suggesting that TNBC would be sensitive to glutaminase inhibition. To test this hypothesis, the metabolic consequences of glutaminase inhibition with CB-839 were examined in two TNBC cell lines, HCC1806 and MDA-MB-231, and one ER+/HER2-line, T47D. CB-839 treatment had a potent effect on the proliferation of the two TNBC cell lines (IC 50 of 20-55nM associated with cell loss at >100 nM) but no effect on the viability of T47D cells ( Fig. 2A and Supplementary Fig. S2A and S2B). BPTES also exhibited selective antiproliferative activity on the two TNBC cell lines ( Supplementary Fig. S2B ) but with an IC 50 of ≥2 µM, consistent with its weaker potency in biochemical assays. To confirm that treatment with 1 µM CB-839 was inhibiting the metabolism of glutamine, the rates of glutamine consumption and glutamate production were quantified for HCC1806 and T47D cell lines (Fig. 2B) . As expected for a glutaminase inhibitor, the rates of glutamine consumption were reduced for both lines. Importantly, the relatively high baseline glutamine consumption rate exhibited by HCC1806 cells was completely inhibited by CB-839 demonstrating the absolute requirement of glutaminase activity to metabolize glutamine in this cell line.
In contrast, glutamine consumption was only partially inhibited in T47D cells suggesting that these cells are capable of metabolizing glutamine through glutaminase-independent pathways.
Like the glutamine consumption rates, glutamate production rates were also dramatically reduced for production in HCC1806 but not in T47D cells. Neither glucose consumption nor lactate production rates were substantially impacted in either cell line, supporting the glutamine-specificity of CB-839 effects and the lack of potential compensatory changes in glycolysis when glutaminase is inhibited ( Supplementary   Fig. S2C ).
The effect of glutaminase inhibition on the levels of intracellular metabolites was also examined in these cell lines. In addition to the expected effects on glutamine (accumulation of substrate) and glutamate (depletion of product), CB-839 reduced the concentration of a number of key metabolites downstream of glutamate within 4 h (Fig. 2D ) and maintained these effects for 24 h (Supplementary Fig. 2D ). In contrast, no changes were observed in cellular glucose levels. Among the downstream metabolites impacted by CB-839 were: i) aspartate (linked to glutamate through aspartate aminotransferase); ii) glutathione (for which glutamate is a key precursor); and iii) the TCA cycle intermediates fumarate, malate, and citrate (via the anapleurotic role of glutamate in producing the TCA cycle intermediate α- Fig. S2F and S2G ). These effects on intracellular metabolite pools are consistent with those previously described for glutaminase siRNA knockdown and BPTES (7, 8, 11) . Highlighting the functional importance of metabolic intermediates derived from glutamate, cell permeable forms of TCA cycle intermediates (oxaloacetate and α-ketoglutartate) and glutathione partially or fully reversed the suppression of TNBC cell viability mediated by CB-839 ( Supplementary Fig. S2H ). However, due to the potential metabolic interconversion of these reagents, additional studies will be required to determine which pathways are most critical for maintenance of cell (Figs. 2C and 2F) . Importantly, the actions of CB-839 were consistent with selective glutaminase inhibition; reduction in OCR OLG was dependent on the presence of glutamine as a substrate in the medium (Figs. 2E and 2F) .
Overall, the impact of CB-839 on cellular metabolism supports an on-target mechanism of action and high degree of TNBC selectivity. The differential effects of CB-839 on glutathione levels were particularly striking. This may reflect the fact that glutamate contributes to glutathione production both as a direct precursor and as a cofactor in the import of cysteine, another glutathione precursor, via the system x c -glutamate/cystine antiporter (30) . Importantly, glutathione concentrations were reduced in HCC1806 but not T47D, demonstrating that certain metabolites derived from glutamine may be independent of glutaminase function in ER+ cancers. Interestingly, a large fraction of glutamate generated from glutamine by glutaminase in HCC1806 cells was recovered in the media, perhaps due to a high demand for cysteine in these TNBC cells (14) . Additional metabolite flux studies will help to elucidate more precisely the impact of CB-839 on metabolic pathways downstream of glutamine.
GAC expression and glutaminase activity are elevated in TNBC.
To expand upon the reported differential expression of glutamine metabolic genes across breast cancer subtypes (14, 16) , we investigated the expression of glutaminase isoforms (GAC and KGA splice forms of GLS plus GLS2) and GLUL in the breast invasive carcinoma dataset from The Cancer Genome Atlas (TCGA) and the breast cancer cell lines in The Cancer Cell Line Encyclopedia (CCLE) (31, 32) . Expression levels were compared across TNBC and receptor-positive subtypes (comprised of ER+/HER2+, ER+/HER2-and ER-/HER+) as well as, in the case of the TCGA dataset, normal breast tissue ( Supplementary Fig. S3A and S3B). These large datasets yielded expression patterns consistent with previous reports (14, 16), including elevated GLUL in primary ER+ tumors. Importantly, the elevated GLS expression in TNBC reported by Kung et al. (16) appears to be largely due to the GAC splice variant, consistent with a recent report (14) . Average GAC expression was elevated in TNBC primary tumors relative to both normal breast tissue and receptor-positive tumor subtypes. In contrast, there was no difference in KGA expression between TNBC and normal tissue. GAC and KGA expression were both lower in receptor- To determine if these gene expression patterns were reflected at the protein level, a panel of breast cell lines was analyzed by Western blot for the expression of GAC, KGA, GLUL and GLS2 (Fig. 3A) . Consistent with the mRNA expression, the majority of TNBC cell lines expressed high levels of both GAC and KGA in comparison with receptor-positive lines. Interestingly, the exceptions were JIMT-1 and HCC1954, both basal-like ER-/HER2+ cell lines (27, 33) , consistent with recent observations that molecular subtypes can also distinguish glutaminase expression patterns (14) The expression of GLUL and GLS2 was more variable and did not display a clear distinction between TNBC and receptor-positive cell lines. Consistent with the GAC and KGA mRNA and protein expression levels, phosphate-activated glutaminase specific activities in lysates prepared from the same breast cancer cell line panel were elevated in TNBC cell lines as compared to the receptor-positive cells (Fig. 3B, Supplementary Fig. S4A ). Supplementary Fig. S5 ), consistent with apoptosis induction following glutamine withdrawal in a subset of breast cell lines (14) .
To determine if the sensitivity of breast cancer cell lines to CB-839 is correlated with their dependence on glutamine, the effect of glutamine withdrawal was tested across the breast cancer cell line panel.
The TNBC cell lines exhibited greater overall dependence on glutamine (Fig. 4C and Supplementary Fig.   S4C ), as noted previously (14, 16) , with the majority of TNBC cell lines showing cell loss when deprived of glutamine (Fig. 4C) . Importantly, across this cell line panel, sensitivity to glutaminase inhibition with CB-839 was highly correlated with dependence on glutamine (Fig. 4D) , suggesting that glutamine supports TNBC cell viability primarily through its glutaminase-mediated conversion to glutamate.
GAC expression, glutaminase activity and metabolite levels predict sensitivity to CB-839.
We hypothesized that the genetic signature that distinguishes TNBC from receptor-positive tumors and normal tissue could be used to identify tumors sensitive to CB-839 treatment. Indeed, across the breast cancer cell line panel, greater sensitivity to CB-839 with regard to proliferation or viability was correlated with higher GAC expression (Fig. 5A) . Although CB-839 inhibits both splice variants of GLS, no correlation between CB-839 sensitivity and KGA expression was observed, supporting a dominant role for the GAC splice variant in the glutamine utilization and dependence of TNBC cell lines. Although the functional distinctions between the GLS splice variants remains to be established, it is possible that potential differences in activity, regulation, or localization make GAC more efficient at supporting a transformed phenotype (6, 15, 22, 23) . In support of this possibility, siRNA knockdown studies in NSCLC have shown that the GAC splice variant of GLS, but not KGA, has an important role supporting tumor cell growth (10).
To expand upon this genetic correlation, the relationship between CB-839 sensitivity and measures of glutaminase function were evaluated across the breast cancer cell line panel. The functional markers evaluated included glutaminase specific activity (see Fig. 3B ), the baseline ratio of intracellular glutamate to glutamine (product to substrate ratio serving as a potential surrogate for glutaminase activity), and the extent to which 1 µM CB-839 promoted accumulation of cellular glutamine or depletion of cellular glutamate (as noted in Fig. 2D ). Greater CB-839 sensitivity was strongly correlated with higher glutaminase specific activity, the most direct functional readout ( Figs. S4D-S4F and S6A-S6C). Accordingly, greater CB-839 sensitivity was associated with higher baseline cellular glutamate to glutamine ratio (Fig. 5C) , greater CB-839-induced cellular glutamine accumulation (Fig. 5D) , and greater CB-839-induced cellular glutamate depletion (Fig. 5E ). Taken together, these observations demonstrate that across a breast cancer cell line panel, sensitivity to CB-839 is correlated with both genetic (GAC expression) and functional markers (glutaminase activity, glutamate:glutamine ratio) of glutamine utilization. Importantly, evaluation of these biomarkers of CB-839 sensitivity in tumor biopsies in the clinic could be used to select patients with the greatest likelihood to respond to CB-839 treatment.
Oral dosing of CB-839 inhibits tumor glutaminase activity and changes metabolite levels.
The in vivo utility of CB-839 was initially evaluated in pharmacodynamic studies. CB-839 was administered orally at a dose of 200 mg/kg to scid/beige mice bearing orthotopically implanted HCC1806 tumors. Tumor, plasma, and selected tissues were collected 4 h after dosing for measurement of CB-839 levels, pharmacodynamic markers (glutamine, glutamate, and aspartate), and glutaminase activity (tumor only). Plasma and tumor CB-839 concentrations of > 1.5 µM or nmol/g, respectively, were achieved demonstrating good systemic exposure (Fig. 6A ). This level of exposure was associated with a robust pharmacodynamic response in the tumor as measured by the suppression of glutaminase activity (Fig. 6B ) and the increase in glutamine and decreases in glutamate and aspartate (Fig. 6C ) in tumor lysates. Furthermore, CB-839 achieved widespread exposure in most mouse tissues (Fig. 6D) .
The exception was brain where exposure was >7-fold lower than tumor or other tissues, indicating that CB-839 does not efficiently cross the blood-brain barrier. Systemic CB-839 exposure was associated with an increase in glutamine in plasma and all tissues with the exception of brain, where exposure was likely limiting, and liver, where the CB-839 insensitive form of glutaminase, GLS2, is expressed (Fig. 6D) .
However, despite high CB-839 exposure, the glutamine increases in plasma and tissues (maximum 2.3-fold in spleen) were not as dramatic as those in tumor (>5-fold). Similarly, in most tissues, CB-839 failed to reduce glutamate or aspartate levels; in the two tissues where glutamate and aspartate reductions were observed (lung and spleen), they were less pronounced than those seen in tumors. Together these results suggest that the pharmacodynamic impact of CB-839 is largely tumor-selective, perhaps due to greater flux through the glutaminase pathway in tumors or efficient compensatory mechanisms in normal tissues.
CB-839 has antitumor activity in xenograft models of TNBC and basal-like breast cancer. The antitumor activity of CB-839 was tested in two breast cancer xenograft models, a primary patientderived TNBC xenograft and a cell line-based xenograft model using the HER2+ basal-like cell line JIMT-1.
The primary patient-derived TNBC model was selected based on high GAC expression, high glutaminase activity, and a high ratio of glutamate to glutamine relative to a panel of other breast tumors and other solid tumors (data not shown). CB-839 was administered at 200 mg/kg twice daily (BID) once the subcutaneously-implanted tumors reached 150 mm 3 . Because CB-839 clearance was relatively high in mice ( Supplementary Fig. S7A ), BID administration was necessary to maintain continuous target coverage. In this model, single agent CB-839 suppressed tumor growth by 61% relative to vehicle control at the end of study (P = 0.0029; Fig. 6E ).
In the JIMT-1 xenograft model, the antitumor efficacy was evaluated by treating established tumors (125 and P = 0.0025 vs. paclitaxel alone). These in vivo efficacy results build upon those previously published using other glutaminase inhibitors in lymphoma and renal cancer models (6, 9, 13, 19) .
In both xenograft studies, CB-839 was well tolerated (even in combination with paclitaxel), with no difference in weight gain between groups (Supplementary Figs. S7B and S7C) and no overt signs of toxicity. This tolerability profile may be reflective of modest pharmacodynamic effects of CB-839 in normal tissues in comparison to tumor (Fig. 6D) , and suggests that this agent may have a favorable therapeutic index in the clinic.
Conclusion.
We report here the discovery and characterization of CB-839, a potent and selective inhibitor of glutaminase. CB-839 displays on-target cellular activity as indicated by its ability to suppress key glutamate-derived metabolic intermediates that support macromolecule synthesis, ATP production, and Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. cellular redox balance. Our work demonstrates that TNBC cells are particularly dependent on glutamine for growth and survival and that blocking this pathway by inhibiting the activity of glutaminase with CB-839 has antitumor activity in both in vitro and in vivo models. This activity is correlated with elevated expression of the GAC splice variant of glutaminase and a high baseline ratio of glutamate to glutamine (product to substrate), two markers that could be used to enrich for responsive patients in clinical trials.
Together, these results suggest that CB-839 may have therapeutic benefit for patients with TNBC and perhaps other glutamine-dependent cancers by selectively blocking the ability of tumor cells to utilize glutamine as a nutrient. 
